Analystreport

Cardiome Pharma Corp (NASDAQ: CRME) was given a new $5.00 price target on by analysts at Canaccord Genuity. They now have a "buy" rating on the stock.

CARDIOME PHARMA CORP OR  (CRME) 
Last cardiome pharma corp or earnings: 5/15 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: cardiome.com/investors